LAPSE:2023.36499
Published Article
LAPSE:2023.36499
Drug Formulation of Securigera securidaca Seed Extracts
Mohamed E. M. Abdelbagi, Ghassab M. Al-Mazaideh, Adil Elhag Ahmed, Fuad Al-Rimawi, Haya Ayyal Salman, Abdulrahman Almutairi, Faraj Ahmad Abuilaiwi, Fadel Wedian
August 3, 2023
seeds are reported to treat a variety of diseases; they contain multiple antidiabetic constituents and are widely used as anti-hyperglycemic, antibacterial, as well as anti-hyperlipidemic agents. The present work aimed to propose tablet formulations containing extracts of S. securidaca seeds in an attempt to obtain antibacterial and anti-hyperglycemic formulations with a more efficient oral hypoglycemic impact, limited side effects, and higher patient compliance for the first time, resulting in multiple benefits. Tablet formulations were created by encapsulating granules from S. securidaca seed extracts with varying concentrations of sodium starch glycolate as a super-disintegrant (0−3%). The final formulations were examined for weight variation, solubility, hardness, water content, disintegration time, friability, drug content (trigonelline and diosgenin), and in vitro drug release. The S. securidaca tablet formulations completed the weight test because the percentage deviation in the personal tablet weight and mechanical resistance from the mean were identified to be within the average range. In accordance with the results, formulations containing diosgenin as well as trigonelline as a super-disintegrant were identified as the ideal formulations. The amount of the active substance released from the tablet (S. securidaca seed extract formulation) was consistent throughout the results with the standard methods recommended by the FDA (94.05%) for diosgenin and 87.25% for trigonelline after 45 min. The acceptable limit, according to the FDA, is not more than (N.L.T.) 80% after 45 min for phase #1. The present study aimed to obtain an optimized formula for S. securidaca extract tablets that met the requirements of a good pharmaceutical preparation according to the United States Pharmacopeia (USP) and National Formulary (NF). This has important implications for the development of novel, effective treatments and significantly advances the development of natural medicine. Our findings are expected to be of interest to researchers, clinicians, and other experts in this field of study. Based on these findings, it can be inferred that the formulation of S. securidaca seed extracts with appropriate and compatible herbal dosage forms has fewer side effects and is more effective than traditional treatments.
Keywords
diosgenin, drug formulation, S. securidaca, trigonelline
Subject
Suggested Citation
Abdelbagi MEM, Al-Mazaideh GM, Ahmed AE, Al-Rimawi F, Ayyal Salman H, Almutairi A, Abuilaiwi FA, Wedian F. Drug Formulation of Securigera securidaca Seed Extracts. (2023). LAPSE:2023.36499
Author Affiliations
Abdelbagi MEM: Department of Chemistry, College of Science, University of Hafr Al Batin, Hafr Al Batin 31991, Saudi Arabia
Al-Mazaideh GM: Department of Pharmaceutical Chemistry, College of Pharmacy, University of Hafr Al Batin, Hafr Al Batin 31991, Saudi Arabia [ORCID]
Ahmed AE: Department of Chemistry, College of Science, University of Hafr Al Batin, Hafr Al Batin 31991, Saudi Arabia
Al-Rimawi F: Department of Chemistry, Faculty of Science and Technology, Al-Quds University, Jerusalem P.O. Box 20002, Palestine [ORCID]
Ayyal Salman H: School of Biological Sciences, Universiti Sains Malaysia, 1112, Persiaran Sains, Gelugor 11800, Pulau Pinang, Malaysia
Almutairi A: Department of Pharmacy Practice, College of Pharmacy, University of Hafr Al Batin, Hafr Al Batin 31991, Saudi Arabia
Abuilaiwi FA: Department of Chemistry, College of Science, University of Hafr Al Batin, Hafr Al Batin 31991, Saudi Arabia [ORCID]
Wedian F: Department of Chemistry, Faculty of Science, Yarmouk University, P.O. Box 560, Irbid 22163, Jordan
Journal Name
Processes
Volume
11
Issue
7
First Page
1955
Year
2023
Publication Date
2023-06-28
Published Version
ISSN
2227-9717
Version Comments
Original Submission
Other Meta
PII: pr11071955, Publication Type: Journal Article
Record Map
Published Article

LAPSE:2023.36499
This Record
External Link

doi:10.3390/pr11071955
Publisher Version
Download
Files
[Download 1v1.pdf] (626 kB)
Aug 3, 2023
Main Article
License
CC BY 4.0
Meta
Record Statistics
Record Views
98
Version History
[v1] (Original Submission)
Aug 3, 2023
 
Verified by curator on
Aug 3, 2023
This Version Number
v1
Citations
Most Recent
This Version
URL Here
https://psecommunity.org/LAPSE:2023.36499
 
Original Submitter
Calvin Tsay
Links to Related Works
Directly Related to This Work
Publisher Version